SCHEDULE: BlackRock Discloses 8.3% Stake in CRISPR Therapeutics

BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 7,987,262 shares, representing 8.3% of the outstanding common stock of CRISPR Therapeutics AG.

Summary

• BlackRock, Inc. has updated its Schedule 13G filing regarding its holdings in CRISPR Therapeutics AG.
• The filing indicates beneficial ownership of 7,987,262 shares of common stock.
• This represents 8.3% of the total outstanding shares of CRISPR Therapeutics AG.
• The filing was made on June 30, 2026, with an amendment number of 1.
• BlackRock, Inc. has sole voting power over 7,841,979 shares and sole dispositive power over 7,987,262 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine ownership disclosure by a major institutional investor and does not provide new operational or financial information about the company.

Positives

• BlackRock, a significant institutional investor, holds a substantial stake (8.3%) in CRISPR Therapeutics, indicating confidence in the company's long-term prospects.
• The clear reporting of sole voting and dispositive power suggests straightforward control over these shares.

Negatives

• The filing does not contain any negative financial or operational information about CRISPR Therapeutics itself, as it is a disclosure of ownership by BlackRock.

Risks

• The primary risk associated with this filing is the potential for BlackRock to alter its holdings, which could impact CRISPR Therapeutics' stock price.
• As a large institutional holder, any significant sale by BlackRock could exert downward pressure on the stock.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from CRISPR Therapeutics AG.

Industry Context

StockSavvy.ai notes that significant holdings by major asset managers like BlackRock in gene editing companies like CRISPR Therapeutics are common, reflecting the sector's high growth potential and the increasing institutional interest in biotechnology.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which can be viewed positively for stability, but also implies potential for future trading activity that could affect share price.
• Management: The filing is a standard disclosure and does not directly impact management's day-to-day operations, but it signals continued institutional interest.
• Creditors: No direct impact on creditors is indicated by this ownership filing.

Next Steps

• BlackRock will continue to monitor its investment in CRISPR Therapeutics AG.
• CRISPR Therapeutics AG will continue its operations and strategic initiatives.

Key Dates

Keywords

CRISPR Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Gene Editing